Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
HYPAQUE-M 75% is an injectable contrast medium used in diagnostic imaging procedures to enhance visualization of internal structures during radiological examinations. The product is a long-established diagnostic agent approved since 1955, indicating it is a foundational imaging tool in radiology. It functions as a radiographic contrast agent to improve image clarity in X-ray and other imaging modalities.
With LOE approaching and moderate competitive pressure (30%), the product is in transition; teams are likely focused on defending market position and managing decline rather than growth expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
HYPAQUE-M offers limited career growth opportunities given its LOE-approaching lifecycle and zero linked job postings, indicating a contracting team footprint. Professionals joining this portfolio should expect roles focused on market defense, cost optimization, and transition planning rather than launch or expansion.
Worked on HYPAQUE-M,75% at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.